PE20251175A1 - Anticuerpos anti-bmp9 y metodos de uso de los mismos - Google Patents
Anticuerpos anti-bmp9 y metodos de uso de los mismosInfo
- Publication number
- PE20251175A1 PE20251175A1 PE2024002739A PE2024002739A PE20251175A1 PE 20251175 A1 PE20251175 A1 PE 20251175A1 PE 2024002739 A PE2024002739 A PE 2024002739A PE 2024002739 A PE2024002739 A PE 2024002739A PE 20251175 A1 PE20251175 A1 PE 20251175A1
- Authority
- PE
- Peru
- Prior art keywords
- antibody
- bmp9
- human
- polynucleotide
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a anticuerpos, y fragmentos de union a antigeno de los mismos, que se unen especificamente a la proteina morfogenetica osea-9 (BMP9), generando que cuando el anticuerpo se une a BMP9 humana inhibe la actividad de BMP9 y la union de BMP9 humana a celulas endoteliales humanas. Tambien se refiere a un polinucleotido aislado que codifica el anticuerpo; un vector que contiene el polinucleotido; la celula huesped que contiene el vector con el polinucleotido, y su metodo de cultivo para producir y recuperar el anticuerpo; una composicion farmaceutica que comprende una cantidad terapeuticamente efectiva del anticuerpo y un portador farmaceuticamente aceptable; la administracion a un individuo que lo necesita de una cantidad terapeuticamente efectiva de la composicion farmaceutica o el anticuerpo, para tratar una enfermedad como la hipertension pulmonar, incluida la hipertension arterial pulmonar.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263347543P | 2022-05-31 | 2022-05-31 | |
| US202263375781P | 2022-09-15 | 2022-09-15 | |
| US202363499808P | 2023-05-03 | 2023-05-03 | |
| PCT/IB2023/055592 WO2023233330A1 (en) | 2022-05-31 | 2023-05-31 | Anti-bmp9 antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20251175A1 true PE20251175A1 (es) | 2025-04-23 |
Family
ID=87036030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2024002739A PE20251175A1 (es) | 2022-05-31 | 2023-05-31 | Anticuerpos anti-bmp9 y metodos de uso de los mismos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240083991A1 (es) |
| EP (1) | EP4532542A1 (es) |
| JP (1) | JP2025518726A (es) |
| KR (1) | KR20250021318A (es) |
| CN (1) | CN119278212A (es) |
| AU (1) | AU2023279258A1 (es) |
| CA (1) | CA3254800A1 (es) |
| CO (1) | CO2024016014A2 (es) |
| IL (1) | IL316700A (es) |
| MX (1) | MX2024012521A (es) |
| PE (1) | PE20251175A1 (es) |
| TW (1) | TW202405002A (es) |
| WO (1) | WO2023233330A1 (es) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| WO2000009560A2 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1871417B1 (en) | 2005-04-15 | 2013-09-11 | Precision Biologics, Inc. | Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers |
| US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
| CA2676529C (en) | 2007-01-24 | 2014-03-25 | Kyowa Hakko Kirin Co., Ltd. | Genetically recombinant antibody composition having enhanced effector activity |
| HK1209769A1 (en) * | 2012-07-02 | 2016-04-08 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient |
| CN107614526A (zh) | 2015-06-05 | 2018-01-19 | 诺华股份有限公司 | 靶向骨形成蛋白9(bmp9)的抗体及其方法 |
| JP2017025011A (ja) * | 2015-07-17 | 2017-02-02 | 協和発酵キリン株式会社 | 抗ｂｍｐ９抗体 |
-
2023
- 2023-05-31 PE PE2024002739A patent/PE20251175A1/es unknown
- 2023-05-31 US US18/326,335 patent/US20240083991A1/en active Pending
- 2023-05-31 IL IL316700A patent/IL316700A/en unknown
- 2023-05-31 JP JP2024570561A patent/JP2025518726A/ja active Pending
- 2023-05-31 CN CN202380038935.6A patent/CN119278212A/zh active Pending
- 2023-05-31 TW TW112120405A patent/TW202405002A/zh unknown
- 2023-05-31 CA CA3254800A patent/CA3254800A1/en active Pending
- 2023-05-31 WO PCT/IB2023/055592 patent/WO2023233330A1/en not_active Ceased
- 2023-05-31 KR KR1020247040863A patent/KR20250021318A/ko active Pending
- 2023-05-31 AU AU2023279258A patent/AU2023279258A1/en active Pending
- 2023-05-31 EP EP23734730.7A patent/EP4532542A1/en active Pending
-
2024
- 2024-10-09 MX MX2024012521A patent/MX2024012521A/es unknown
- 2024-11-25 CO CONC2024/0016014A patent/CO2024016014A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202405002A (zh) | 2024-02-01 |
| CA3254800A1 (en) | 2023-12-07 |
| AU2023279258A1 (en) | 2024-09-26 |
| US20240083991A1 (en) | 2024-03-14 |
| CN119278212A (zh) | 2025-01-07 |
| MX2024012521A (es) | 2024-11-08 |
| CO2024016014A2 (es) | 2024-12-30 |
| WO2023233330A1 (en) | 2023-12-07 |
| IL316700A (en) | 2024-12-01 |
| EP4532542A1 (en) | 2025-04-09 |
| JP2025518726A (ja) | 2025-06-19 |
| KR20250021318A (ko) | 2025-02-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR111203A1 (es) | Inmunoconjugados | |
| PE20220142A1 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| PE20210342A1 (es) | Anticuerpos anti-sirpa y metodos de utilizacion de los mismos | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| EA202190986A1 (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit | |
| EA201101242A1 (ru) | Полностью человеческие антитела, специфические для cadm1 | |
| US10208126B2 (en) | Methods of treating aplastic anemia by administering anti-CD26 antibodies | |
| AR085955A1 (es) | Proteinas de union al antigeno | |
| PE20090518A1 (es) | Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18) | |
| PE20220489A1 (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| AR128686A1 (es) | MOLÉCULAS DE UNIÓN CONTRA FRa | |
| IL273578B1 (en) | Antibodies targeting pdl1 and methods of use thereof | |
| MX2022011951A (es) | Anticuerpos de la lectina 15 similar a la inmunoglobulina que se une a acido sialico (siglec15) y usos de los mismos. | |
| BR112022005044A2 (pt) | Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento | |
| AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
| AR131398A1 (es) | Tratamiento de enfermedades autoinmunitarias | |
| PE20251175A1 (es) | Anticuerpos anti-bmp9 y metodos de uso de los mismos | |
| PE20251275A1 (es) | Agentes aglutinantes 5t4 y usos de los mismos | |
| AR132064A1 (es) | Anticuerpos anti-cldn6 y métodos de uso | |
| AR125857A1 (es) | ANTICUERPOS PARA EL TRATAMIENTO DE a-SINUCLEINOPATÍAS | |
| AR132063A1 (es) | Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso | |
| AR132041A1 (es) | Anticuerpos cd16a y métodos de uso | |
| CN108101984A (zh) | 骨硬化蛋白单链抗体的制备方法和用途 | |
| AR132040A1 (es) | Anticuerpos muc1 y cd16a y métodos de uso |